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Abstract
Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules 
result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmaco-
dynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic 
uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated throm-
botic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize 
treatment and reduce costs.
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Key Points 
To assess the optimal treatment scheme and minimize 
unnecessary use of the highly expensive orphan drug eculi-
zumab, therapeutic drug monitoring should be performed.
Treatment algorithms, based on serum eculizumab levels 
and total complement activity (CH50), should be devel-
oped to guide individual dosing regimens.
1 Introduction
With orphan drug status in 2003 and approval in 2007, ecu-
lizumab  (Soliris®) was the first drug targeting the comple-
ment system, specifically complement component C5 [1–3]. 
Since the approval of eculizumab, many trials have been 
conducted and various drugs targeting different proteins of 
the complement system are in the pipeline [4]. Until now, 
marketing authorization for eculizumab has been obtained 
for the treatment of paroxysmal nocturnal hemoglobinuria 
(PNH), atypical hemolytic uremic syndrome (aHUS), and 
refractory generalized myasthenia gravis (gMG) [1, 5, 6]. 
Noteworthy is the off-label use of eculizumab as a broad 
spectrum of other diseases (Table 1) [7].
Like other orphan drugs, costs as high as €500,000 per 
patient per year are associated with eculizumab therapy 
[8]. Consequently, eculizumab is considered one of the 
world’s most expensive drugs. Second, the burden for 
patients is considerable since eculizumab has to be admin-
istrated intravenously every 2 weeks, potentially for a life-
time. Third, there are large interindividual variations in 
pharmacokinetics (PK) [9, 10], and, lastly, treatment is not 
without risks. The most prominent risk is the susceptibility 
to infection with Neisseria meningitidis (meningococcus) 
[11]. Furthermore, evidence is accumulating regarding the 
potential (long-term) adverse effects of eculizumab, such 
as hepatotoxicity [12, 13].
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Taking these factors into consideration, the infinitesimal 
data regarding dose adaptations guided by either measur-
ing drug concentration or efficacy markers (complement 
system) is striking. In this review, we provide insight into 
the PK and pharmacodynamics (PD) of eculizumab, for 
both reported on- and off-label use. Furthermore, PK tar-
gets within different diseases are discussed to optimize 
dosing. To conclude, the possibility, and above all neces-
sity, of dose individualization will be discussed, together 
with the tools to achieve tailored patient care.
1.1  The Complement System
The complement system is an important part of innate 
immunity and consists of three different pathways, all con-
verging at C3, the central complement component (Fig. 1). 
The classical pathway (CP) and lectin pathway (LP) are, 
respectively, triggered by antibodies (such as the case in 
gMG) and mannose-containing sugars on pathogens. The 
alternative pathway (AP) is unique since spontaneous auto-
activation is always present and can be further triggered by 
bacterial components such as lipopolysaccharide and bac-
terial toxins [14]. Activation of each pathway leads to the 
formation of the C3 convertase (C3bBb) which can cleave 
C3, leading to chemotaxis and opsonization with C3a and 
C3b, respectively. The generation of large amounts of C3b 
results in the formation of C5 convertase (C3bBbC3b). In 
turn, C5 convertase can cleave C5, thereby producing the 
second anaphylatoxin C5a, and C5b, which can bind com-
plement proteins C6, C7, C8 and C9 to form the end product 
of the complement system, the membrane attack complex 
or C5b-C9 (C5b-C9), which causes cell lysis (Fig. 1). Nor-
mally, the complement system is tightly controlled by regu-
latory proteins present in both the fluid phase and on the cell 
surface [14, 15].
1.2  Pathogenesis of Complement‑Mediated 
Diseases
Together with our growing knowledge of the comple-
ment system and its role in different diseases, evidence has 
emerged for complement blockage with drugs. Eculizumab 
was approved by the European Medicines Agency (EMA) 
and US Food and Drug Administration (FDA) as standard 
treatment for PNH, aHUS and gMG in 2007, 2011, and 
2017, respectively [1, 6, 16, 17]. Eculizumab administration 
is reported in two disease situations: primarily in diseases 
resulting from complement dysregulation (e.g. PNH and 
Table 1  Reported use of eculizumab in light of pharmacokinetic and pharmacodynamic data
HSCT-TMA hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Ig immunoglobulin
a Data on serum eculizumab (trough) levels were considered sufficient for pharmacokinetic data
b Data regarding serum eculizumab levels in relation to complement blockade
Disease Pharmacokinetic 
data  availablea
Pharmacodynamic 
data  availableb
References
Atypical hemolytic uremic syndrome Yes Yes [6, 9, 10, 52, 53, 56, 60, 
61, 75, 82, 86–92]
Paroxysmal nocturnal hemoglobinuria Yes Yes [1, 2, 16, 32, 42, 57, 59, 
68, 73, 74, 93–98]
Refractory generalized myasthenia gravis Yes Yes [5, 36, 99]
Shiga toxin producing Escherichia coli hemolytic uremic syndrome No No [29, 100]
Multifocal motor neuropathy Yes Yes [62]
Antibody-mediated kidney rejection No No [48, 101]
C3 glomerulopathy (including dense deposit disease) Yes No [22, 26]
Age-related macular degeneration Yes No [28, 102]
AQP4 IgG-positive neuromyelitis optica Yes [45]
Systemic lupus erythematosus Yes Yes [43]
HSCT-TMA Yes Yes [18, 25, 30]
Guillain-Barré No No [103]
Psoriasis Yes No [3]
Rheumatoid arthritis Yes Yes [3, 44, 73]
Dermatomyositis Yes No [46]
Idiopathic membranous glomerulopathy Yes Yes [3, 73]
Demyelinating neuropathy with CD59 p.Cys89Tyr mutation No No [104]
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aHUS) and subsequently in diseases with extensive com-
plement activation with inflammation (e.g. gMG) [18–30]. 
For the purpose of this review, the most prominent diseases 
with reported eculizumab therapy are described, in light of 
sufficient PK and PD data being available.
1.2.1  Paroxysmal Nocturnal Hemoglobinuria
PNH is a rare form of acquired hemolytic anemia associ-
ated with high mortality and morbidity. It has an estimated 
incidence of one to two cases per million and usually affects 
Fig. 1  The complement sys-
tem, which consists of three 
pathways that all converge 
at C3. The classical pathway 
is depicted in the left upper 
quadrant, the lectin pathway is 
depicted in right upper quad-
rant, and the alternative path-
way is depicted in the middle on 
the right. After activation, C3 
convertases (C2aC4a or C3bBb) 
are formed, and subsequently 
C5 convertases (C2aC4bC3b 
or C3bBbC3b), resulting in the 
formation of the lytic pore and 
end product of the complement 
system (C5b-C9).To prevent 
overactivation, the complement 
system is tightly controlled by 
various complement regula-
tors such as factor H and factor 
I. Eculizumab is a human-
ized (chimeric) monoclonal 
antibody and is able to bind one 
or two C5 molecules, thereby 
preventing the cleavage of C5 
into C5a and C5b, and hence 
blocking formation of C5b-C9. 
Fb factor b, MAC membrane 
attack complex, MBL mannose 
binding lectin
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adult patients [31, 32]. PNH is caused by a non-malignant 
clonal expansion of hematopoietic stem cells containing a 
somatic mutation in a gene located on the X-chromosome 
called phosphatidylinositol glycan complementation class 
A [2]. As a result, affected stem cells are deficient of glyco-
syl phosphatidylinositol anchored proteins. In patients with 
PNH, clonal expansion results in the production of cells, 
such as erythrocytes, granulocytes and platelets, that lack the 
expression of glycosyl phosphatidylinositol anchored com-
plement regulatory proteins CD55 and CD59. Due to the 
absence of complement regulators CD55 and CD59, eryth-
rocytes are susceptible for complement activation on the cell 
surface, in particular causing hemolysis and thrombosis [15]. 
Before the era of eculizumab, thrombosis accounted for up 
to 65% of deaths, with a thrombosis incidence of 29–44% 
[31].
1.2.2  Atypical Hemolytic Uremic Syndrome
Atypical HUS is a rare and severe form of thrombotic 
microangiopathy (TMA) resulting in mechanical hemolytic 
anemia, thrombocytopenia, and acute kidney injury [33]. 
Atypical HUS results from an uncontrolled overactivation 
of AP due to pathogenic mutations of, or acquired autoan-
tibodies directed against, complement regulatory proteins. 
This complement dysregulation causes endothelial activa-
tion and injury, resulting in platelet aggregation, formation 
of thrombi, and mechanical hemolysis. Atypical HUS has 
an estimated incidence of 0.23–0.42 cases per million and 
affects all ages, with a slightly higher incidence in childhood 
when compared with adults [34]. Although TMA affects pre-
dominantly the renal vasculature, extrarenal involvement is 
reported [33, 35]. Before the implementation of eculizumab, 
mortality was as high as 25% in the acute phase of the dis-
ease and over 50% of patients reached end-state renal disease 
after their first presentation.
1.2.3  Refractory Generalized Myasthenia Gravis
Generalized MG is a rare and acquired form of neuromus-
cular autoimmune disorder. It occurs in the presence of anti-
bodies, and up to 80% is directed against the acetylcholine 
receptor at the postsynaptic membrane of the neuromus-
cular junction. Antibodies (immunoglobulin [Ig] G1 and 
IgG3 isotypes) are known to activate CP, ultimately leading 
to C5b-C9 deposition on the postsynaptic membrane, and 
consequently disruption of the acetylcholine receptors. Due 
to chemotaxis and cell lysis associated with complement 
activation, the postsynaptic membrane becomes less sen-
sitive to the released acetylcholine, hence nerve impulses 
will be inhibited [36–39]. Generalized MG has an estimated 
incidence of up to 10 per million, and patients experience 
progressive muscle weakness and fatigue. Due to respira-
tory failure, patients are frequently admitted to the intensive 
care unit, and, in the case of delayed intervention, this can 
eventually lead to death [36, 37].
1.2.4  Hematopoietic Stem Cell Transplantation‑Associated 
Thrombotic Microangiopathy
Secondary TMA is frequently seen in patients after hemat-
opoietic stem cell transplantation (HSCT) [18]. Mimick-
ing aHUS, the complement system plays a crucial role in 
developing severe HSCT-TMA [18, 25, 40]. Particularly in 
patients presenting with severe HSCT-TMA, the mortality 
rate and severity of chronic sequelae are high. Severe TMA 
affects 20–30% of HSCT recipients and is characterized by 
proteinuria and elevated levels of sC5b-C9, in addition to 
TMA.
2  Method
A literature search of both the PubMed and Embase elec-
tronic databases was performed in May 2017. The specific 
strings used for both search engines are rendered below. The 
main search terms were ‘eculizumab’, ‘pharmacokinetics’, 
and ‘pharmacodynamics’. In total, 73 and 766 articles were 
found in PubMed and Embase, respectively, and titles were 
screened by KW, followed by screening of the abstract and 
full text. We excluded languages other than English and 
Dutch (35), duplicates (65), case reports that included less 
than four cases (81), articles in which no full-text was avail-
able (19), and articles that did not include PK or PD data 
(526). Furthermore, we choose to focus on a limited number 
of diseases (namely PNH, aHUS, HSCT-TMA, and gMG). 
Miscellaneous articles were added to supply background 
information and additional PK and PD information as sup-
plied to the EMA and FDA.
2.1  PubMed
((“Eculizumab” [Supplementary Concept]  OR 
eculizumab[tiab] OR soliris[tiab]) AND (“pharmacology” 
[Subheading] OR “Pharmacology, Clinical”[Mesh] OR 
“Pharmacokinetics”[Mesh] OR “Drug Interactions”[Mesh] 
“Dose-Response Relationship, Drug”[Mesh] OR 
Pharmaco*[tiab] OR exposure*[tiab] OR drug 
monitoring[tiab] OR drug concentration*[tiab] OR tar-
get concentration*[tiab] OR clinical pharmacolog*[tiab] 
OR drug interact*[tiab] OR adverse effect*[tiab] OR 
adverse event*[tiab] OR adverse drug event*[tiab] OR 
contraindication*[tiab] OR contra-indication*[tiab] OR 
dose-response[tiab]))
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2.2  Embase
[Adverse Drug Reaction, Drug Administration, Drug Con-
centration, Drug Dose, Drug Therapy, Drug Toxicity, Intra-
venous Drug Administration, Pharmaceutics, Pharmacoki-
netics, Pharmacology]
(exp eculizumab/ae, ad, cr, do, dt, to, iv, pr, pk, pd) OR 
(Eculizumab OR soliris).ti,ab,kw.
AND exp drug exposure/ or exp drug safety/ or exp phar-
macodynamics/ or exp pharmacokinetics/ or exp clinical 
pharmacology/ or pharmacokinetic*.ti,ab,kw. or pharma-
codynamic*.ti,ab,kw. or drug interact*.ti,ab,kw. or adverse 
effect*.ti,ab,kw. or adverse event*.ti,ab,kw. or adverse drug 
event*.ti,ab,kw. or contraindication*.ti,ab,kw. or contra-
indication*.ti,ab,kw. or dose-response.ti,ab,kw.
3  Pharmacokinetic (PK) Properties 
of Eculizumab
Eculizumab  (Soliris®, Alexion Pharmaceuticals, Inc., New 
Haven, CT, USA) is a humanized chimeric monoclonal 
antibody consisting of a human framework build of IgG2 
and IgG4 composed of variable regions of murine origin 
(Fig. 1). The eculizumab dose depends on the indication 
and weight of the patient (dose adjustment for patients with 
a body weight < 40 kg). The PK of eculizumab in healthy 
subjects have not been studied [41]. In 1999, phase I stud-
ies were performed in rheumatoid arthritis (RA; C97-001-
01) and systemic lupus erythematosus (SLE; C97-002-01) 
patients, followed by phase II multiple-dose studies in 2002 
conducted in patients with RA (C01-004), idiopathic mem-
branous glomerulopathy (IMG, C99-004), and PNH (C02-
001). Pilot studies have also been performed in patients 
with dermatomyositis (C99-007) and psoriasis (C99-007) 
[42–48].
3.1  Absorption, Distribution, Metabolism, 
and Excretion
The characteristics of eculizumab are similar to other 
monoclonal antibodies. Eculizumab is administered as an 
intravenous infusion in 25–45 min, with a maximum of 2 h 
and 4 h in patients > 12 and < 12 years of age, respectively 
(see Table 2 for different dosage regimens for each disease) 
[41]. After intravenous administration, eculizumab is pri-
marily distributed in blood plasma. Limited distribution in 
cerebrospinal fluid has been described, with concentrations 
5000-fold lower than in plasma [45]. Distribution to other 
tissues has not been described in human studies. In vivo ani-
mal studies and in vitro studies with normal human tissues 
showed intracellular distribution to a wide variety of cells, 
consistent with expected C5 localization.
As described for other monoclonal antibodies, eculi-
zumab is internalized by either pinocytosis or binding to 
the Fcγ receptor, and is subsequently degraded by lysosomes 
to peptides and amino acids. Recycling of eculizumab can 
occur via binding to the neonatal Fc receptor (FcRn). How-
ever, the eculizumab–C5 complex does not dissociate effi-
ciently in the endosome. Hence, eculizumab catabolism is 
mainly driven by target-mediated drug disposition [49]. 
Eculizumab contains no known active metabolites [41, 50, 
51]. Due to its molecular size, eculizumab is not excreted 
in urine, except in patients with heavy proteinuria, where 
eculizumab concentrations as high as 56 µg/ml have been 
detected [52, 53].
3.2  Eculizumab Population PK Analysis
The eculizumab concentration in serum depends on vari-
ous factors. The dose is based on weight and the underlying 
disease, with the exception of patients with a body weight 
< 40 kg; this group receives a weight-based regimen. To 
identify the optimal dose of eculizumab necessary to block 
complement, six single-dose studies were performed in 
patients with RA (C97-001-01) and SLE (C97-002-01) 
[3]. Patients were infused with a single dose, ranging 
from 0.1 to 8 mg/kg of eculizumab in 30 min (Tables 3, 
4). As reported in the scientific discussion of the EMA, 
these single-dose studies in RA patients yielded a mean 
clearance (CL) of 0.26 ml/kg/h, with a central volume of 
distribution (Vd1) of 15 ml/kg and peripheral volume of 
distribution (Vd2) of 20 ml/kg [42]. The estimated Vd 
at steady state was calculated at 35 ml/kg, and, with this 
Vd, the estimated half-life was 93 h (3.9 days). The area 
under the curve (AUC) was calculated at 24,467.6 µg·h/
ml. A twofold increase in the eculizumab dose from 4 to 
8 mg/kg in RA and SLE yielded an increase of 60% and 
15% in mean maximum concentration (Cmax), respectively 
(Table 3). Furthermore, the AUC increased by 70% and 
103% in RA and SLE, respectively (Table 3). Both distri-
bution and half-life were dose-dependent (Table 3) [3, 42]. 
One highly interesting observation was the presence of a 
second peak after 2 days postdose, which was most likely 
related to drug recycling from the endosome back into the 
bloodstream, as described for other monoclonal antibodies 
[54]. This peak is most often seen in single-dose, phase 
I or II studies due to timing of blood sampling, which is 
more frequent. The concentration of this second peak is 
minimal compared with the first peak and does not impact 
the overall drug exposure or complement inhibition; thus, 
it is presumed not to be therapeutically significant (Alex-
ion, personal correspondence) [54].
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Table 2  Dosage scheme in different patient populations
aHUS atypical hemolytic uremic syndrome, CH50 classical pathway inhibition, gMG generalized myasthenia gravis, HSCT hematopoietic stem 
cell transplantation, PNH paroxysmal nocturnal hemoglobinuria, sC5b-C9 soluble C5b-C9, TMA thrombotic microangiopathy
a Within 72 h when sC5b-C9 is > 244 ng/mL, when CH50 was no longer suppressed, or after 7 days. In case of the remaining complement activ-
ity (CH50 > 10% and elevated sC5b-C9, the dose should be increased by 300 mg/dose to a maximum of 1200 mg/dose [18]
Patient group Induction Maintenance
PNH 600 mg every week for 4 weeks 900 mg in the fifth week, every 14 days thereafter
aHUS-gMG 900 mg every week for 4 weeks 1200 mg in the fifth week, every 14 days thereafter
 Pediatric population PNH and aHUS < 40 kg
  30 to < 40 kg 600 mg every week for 2 weeks 900 mg in the third week, every 14 days thereafter
  20 to < 30 kg 600 mg every week for 2 weeks 600 mg in the third week, every 14 days thereafter
  10 to < 20 kg 300 mg once 300 mg in the second week, every 14 days thereafter
  5 to < 10 kg 300 mg once 300 mg in the second week, every 21 days
HSCT-TMA 900 mg, second dose when:a 1200 mg every 2 weeks, when steady CH50 suppression is achieved and TMA 
parameters, together with sC5b-C9 levels, normalize
 Pediatric population < 40 kg
  30 to < 40 kg 600 mg second dose  whena 900 mg every 2 weeks, when steady CH50 suppression is achieved and TMA 
parameters, together with sC5b-C9 levels, normalize
  20 to < 30 kg 600 mg second dose  whena 600 mg every 2 weeks, when steady CH50 suppression is achieved and TMA 
parameters, together with sC5b-C9 levels, normalize
  10 to < 20 kg 600 mg second dose  whena 300 mg every 2 weeks, when steady CH50 suppression is achieved and TMA 
parameters, together with sC5b-C9 levels, normalize
  5 to < 10 kg 300 mg second dose  whena 300 mg every 2 weeks, when steady CH50 suppression is achieved and TMA 
parameters, together with sC5b-C9 levels, normalize
Table 3  Non-compartmental analysis
aHUS atypical hemolytic uremic syndrome, AUC ∞ area uder the curve from time zero to infinity, Cmax maximum concentration, Ctrough trough 
concentration, PT plasmatherapy, RA rheumatoid arthritis, SD standard deviation, SLE systemic lupus erythematosus
Population No. of 
partici-
pants
Eculizumab 
dosage (mg/
kg)
Clearance 
(ml/h) ± SD
Central 
volume of 
distribution 
(ml) ± SD
AUC ∞ (µg·h/
ml) ± SD
Cmax (µg/
ml) ± SD
Ctrough (µg/
ml) ± SD
Half-life 
(h) ± SD
References
RA (C97-
001)
6 4 16.2 ± 7.2 7500 ± 4700 22,200 ± 13,700 111 ± 53 Unknown 281 ± 298 [3]
RA (C97-
001)
6 8 20.3 ± 7.2 5000 ± 3600 37,800 ± 5900 182 ± 19 Unknown 197 ± 198 [3]
SLE (C97-
002)
3 4 19.3 ± 5.2 4200 ± 1500 15,600 ± 5000 139 ± 25 Unknown 162 ± 88 [3]
SLE (C97-
002)
3 8 19.1 ± 8.1 3900 ± 1800 31,600 ± 9100 160 ± 10 Unknown 141 ± 6 [3]
aHUS 
patients 
with PT 
(C08-003, 
C09-001r)
48 See Table 2 3660 Unknown Unknown Unknown Unknown 1.26 [56, 61]
Pediatric 
aHUS 
patients 
(C10-003)
22 See Table 2 10.4 5230 Median 
141,741.4 
(range 
43,652.9–
261,814.4)
515.4 (range 
264.7–
1094.4)
256.7 (range 
50.2–
531.1)
290 [60]
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Multiple-dose studies were conducted in three patient 
groups with RA (C01-004), IMG (C99-004), and PNH (C02-
001). With the use of a two-compartment model, PK param-
eters were calculated (see Table 4). At therapeutic doses, 
eculizumab shows linear PK, indicating saturation of the 
drug target [42].
The population PK of eculizumab in PNH patients have 
previously been described using a one-compartment model 
(Table 4). CL was estimated to be 0.3 ml/kg/h, with a Vd of 
110.3 ml/kg, which was slightly larger than the estimated 
serum volume of patients [3]. The elimination rate (K) was 
0.0028 l/h, which resulted in a half-life of approximately 
271.7 h (11.3 days). Of note, in the study by de Latour et al., 
trough concentration (Ctrough) varied from 18 to 643 µg/ml 
and half-life was highly variable, ranging from 4 to 21 days 
[55]. In PNH, eculizumab Ctrough measured at week 26 was 
97 ± 60 µg/ml. Ctrough levels remained stable during the 
maintenance phase (see Table 2 for the dosing regimen) [3, 
56]. During the follow-up of patients in both pivotal trials 
(extension study, E05-001), Ctrough concentrations < 35 µg/ml 
were repeatedly observed in 10% of patients; this correlated 
with rapid eculizumab CL > 0.4 ml/kg/h or a shorter half-
life < 130 h. In half of the patients, breakthrough hemoly-
sis was successfully treated by decreasing the eculizumab 
dosing interval. Overall, 10% of patients needed frequent 
changes in dosing interval to sustain remission [57].
In the group of aHUS patients, PK were best described 
using a one-compartment model. In total, 57 patients from 
C08-002A/B, C08-003 A/B, and C09-001r were included 
in the analysis (see Tables 3 and 4). CL was estimated at 
0.2 ml/kg/h and Vd was 87.7 ml/kg. Ctrough concentrations 
measured at week 26 in aHUS were 242 ± 101 µg/ml, with 
an estimated half-life of 291 h (12.1 days) [56]. PK data of 
both prospective trials (C08-002 A/B and C08-003 A/B) 
showed Ctrough levels of 93 and 113 µg/ml, respectively, in 
adults, and 104 and 109 µg/ml, respectively, in adolescent 
Table 4  Population pharmacokinetic analyses
aHUS atypical hemolytic uremic syndrome, CI confidence interval, gMG generalized myasthenia gravis, HSCT-TMA hematopoietic stem cell 
transplantation-associated thrombotic microangiopathy, IMG idiopathic membranous glomerulopathy, NA not applicable, PNH paroxysmal noc-
turnal hemoglobinuria, RA rheumatoid arthritis, RSE relative standard error, SD standard deviation, SLE systemic lupus erythematosus, Vd vol-
ume of distribution
Population No. of 
partici-
pants
Clear-
ance (ml/
kg/h ± SD)
Central 
volume of 
distribution 
(ml/kg ± SD)
Peripheral 
volume of 
distribution 
(ml/kg ± SD)
Intercom-
partmental 
clearance 
(ml/kg/h)
Elimination 
constant (1/h)
Half-life 
(h) ± SD
Effect of 
weight 
on Vd
References
RA (C97-
001)
10 0.262 15.04 20 Unknown Unknown 92.9 NA [42]
RA (C97-
001)
121 0.3 ± 0.12 12.7 ± 8.54 42.3 ± 9.7 0.54 ± 0.16 Unknown Unknown NA [73]
SLE (C97-
002)
6 0.3 ± 0.11 18.7 ± 4.8 20.6 ± 10.84 0.59 ± 0.56 Unknown Unknown NA [73]
RA (C01-
004)
111 0.230 12.5 44.4 Unknown Unknown 131.33 NA [42]
IMG (C99-
004)
71 0.41 ± 0.14 64.9 ± 31.5 149.5 ± 44.92 0.21 ± 0.17 Unknown Unknown NA [73]
PNH (C02-
001)
11 0.25 ± 0.069 32.5 ± 16.5 26.5 ± 7.37 0.21 ± 0.06 Unknown Unknown NA [73]
PNH (C04-
001)
40 0.311 ± 0.13 110.3 ± 17.9 NA NA 0.0028 ± 0.0008 271.7 ± 81.6 NA [73]
gMG (ECU-
MG-301, 
C08-001)
75 7.37 ml/kg 
[95% CI 
6.62–8.2]
2210 ml 
[95% CI 
1940–
2530]
2400 ml 
[95% CI 
2040–2820]
182 ml/h 
[95% CI 
73.3–454]
Unknown Unknown 0.634 
[95% 
CI 
0.494–
0.774]
[5]
aHUS 
(C08-002, 
C08-003, 
C09-001r)
57 0.208 87.7 NA NA Unknown 291 NA [56, 61]
HSCT-TMA 18 1.4 (RSE of 
9%)
81.7 (RSE of 
21%)
NA NA Unknown Unknown NA [18]
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patients. The AUC during the maintenance phase in both 
trials was 77,693 µg·h/ml and 104,228 µg·h/ml, respectively, 
in adults, and 104,228 µg·h/ml and 99,956 µg·h/ml, respec-
tively, in adolescents. The observed Cmax was up to 431 µg/
ml [56].
The PK properties of eculizumab in gMG were best 
described using a two-compartment model (see Table 4) 
[5, 38, 58]. Data from two studies were combined to best 
describe the PK. Fourteen participants from a double-blind, 
placebo-controlled, randomized, crossover trial (C08-001) 
and 126 participants from a double-blind, placebo-con-
trolled, randomized trial (ECU-MG-301) were included in 
the analysis. CL was estimated at 0.09 ml/kg/h, with a Vd1 
of 27.6 ml/kg and Vd2 of 30 ml/kg (median weight of 80 kg 
in the eculizumab arm). Eculizumab Ctrough concentrations 
were approximately twofold different at steady state when 
comparing both studies. Following a maintenance dose of 
1200 mg, Cmax and Ctrough levels reported at week 26 were 
738 ± 288 µg/ml and 341 ± 172 µg/ml. Interindividual vari-
ability was high, and CL and Vd were up to 42% and 24%, 
respectively [5, 58].
Finally, another study assessed the PK properties of 
eculizumab in patients with HSCT-TMA. Eculizumab CL 
ranged from 0.23 to 3.39 mL/kg/h during the induction 
phase. Important to note is the high number of erythrocyte 
and platelet transfusions due to severe and persistent gastro-
intestinal bleeding, which explains the high CL rate. At the 
fifth week, CL decreased to a mean CL (± standard devia-
tion [SD]) of 0.35 ml/kg/h (± 0.25). PK modeling with a 
one-compartment model of eculizumab therapy in HSCT 
recipients showed a high variability of eculizumab CL of 
1.4 ml/kg/h (relative standard error 9%), especially within 
the first weeks of treatment [18].
3.3  Factors Influencing Eculizumab Concentrations
Several covariates have been identified to impact the PK of 
eculizumab, including age, weight, C5 concentrations, C5b-
C9 concentrations, human anti-human antibodies (HAHAs), 
plasma exchange therapy, and pregnancy. The impact of 
these covariates will be discussed in the next paragraphs.
3.3.1  Effect of Age and Weight
The most important covariate is body weight of the patient, 
especially in the pediatric population [9]. Consequently, in 
patients with a body weight < 40 kg, the eculizumab dose 
scheme is adjusted. Eculizumab PK in children have been 
investigated in two open-label studies, in both PNH (n = 7) 
and aHUS (n = 22) patients [59, 60].
In the open-label, phase I/II study (M07-005) conducted in 
seven PNH patients ranging in age from 11 to 17 years, patients 
received eculizumab according to the standard protocol 
(600 mg weekly for 4 weeks, followed by 900 mg at week 
5 and every 14 days thereafter). Eculizumab concentrations 
reached a plateau after 4 weeks. After 12 weeks, the median 
Ctrough concentrations were 192.5 µg/ml (range 124.2–321.1), 
with a median Cmax of 425.4 µg/ml (220.5–556.1) [59]. No 
data regarding CL and Vd were described.
Based on population PK analysis of the three pivotal 
trials of aHUS (C08-002, C08-003, and C09-001r), CL 
(± SD) per weight category (> 40, 30–40, 20–30, 10–20, 
and 5–10 kg) was estimated at 15.1 (± 6.5), 7.6, 6 (± 1.46), 
5.49 (± 0.24), and 3.6 (± 1.3) ml/h, respectively, resulting 
from an allometric relationship between weight and CL 
[56]. Furthermore, in the prospective, open-label, non-
randomized, single-arm C10-003 trial, 22 pediatric aHUS 
patients > 1 month of age and a body weight of 4.9 kg were 
included [60]. Median weight was 20 kg (range 7–95 kg). 
Patients received different doses of eculizumab, with an 
interval of 14–21 days based on weight, as described in the 
summary of product characteristics [61]. CL and Vd were 
0.54 ml/kg/h and 261.5 ml/kg (based on a median weight 
of 20 kg), respectively [60]. Overall, patients had a Cmax of 
515.4 µg/ml (range 264.7–1094.4) and Ctrough of 256.7 µg/
ml (range 50.2–531.1), which is higher than in the adult 
population. The elimination half-life was 290 h (12 days). 
Overall, patients had a median AUC of 141,741.4 µg.h/ml 
(range 43,652.9–261,814.4) at steady state. The power func-
tion of body weight on CL and Vd was estimated at 0.796 
(95% confidence interval [CI] 06–0.99) and 0.715 (95% CI 
0.59–0.84), respectively. Eculizumab appeared safe and 
effective in pediatric patients [41, 60].
3.3.2  C5 Concentration
One eculizumab molecule can bind two C5 molecules. Since 
eculizumab–C5 complexes are not recycled via FcRn, C5 
levels influence the target-mediated drug disposition of 
eculizumab. C5 levels are approximately 80–110 µg/ml in 
healthy controls, but are highly variable per individual and 
per time point depending on the underlying disease and the 
amount of complement activation [10].
3.3.3  Soluble C5b‑9 Levels
Three articles were recently published suggesting that 
soluble C5b-9 (sC5b-C9) levels may impact eculizumab 
exposure [10, 18, 52]. Since eculizumab is capable of not 
only binding C5 but also sC5b-C9 with lower affinity, it is 
physiologically plausible that increased levels of sC5b-C9 
at the initiation of therapy correlate with lower eculizumab 
concentrations. Jodele et al. even showed that pretreatment-
measured sC5b-C9 levels correlated with eculizumab CL 
[18].
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3.3.4  Intravenous Administration of Immunoglobulins
Monoclonal antibodies can be cleared via non-specific 
endocytosis and uptake via Fcγ receptors on phagocytes; 
however, they are protected intracellularly from degradation 
by the FcRn. In case of saturation of this FcRn, due to, for 
example, a high load of immunoglobulins, increased elimi-
nation of monoclonal antibodies can occur [50]. A study 
performed in patients with multifocal motor neuropathy, 
who were treated with eculizumab according to PNH proto-
col, and concomitant intravenous immunoglobulins (IVIgs), 
showed a significantly lower eculizumab Ctrough. Eculizumab 
concentrations were measured in patients who received IVIg 
therapy, and a median of 79 µg/ml (interquartile range [IQR] 
55–108) was reported, versus 120 µg/ml (IQR 96–147) in 
patients who did not receive IVIg [62]. No statistical sig-
nificance was observed in hemolytic complement activity, 
although more patients with IVIg had detectable total com-
plement activity > 20% [62].
3.3.5  Human Anti‑human Antibodies
As with any humanized antibody therapy, the risk of devel-
oping (neutralizing) HAHAs is present. Analysis of a cohort 
of 75 PNH patients with a median of 7.5 years of eculizumab 
therapy revealed no HAHAs [63]. In the TRIUMPH trial, 
one patient developed HAHAs, however this did not seem 
to affect eculizumab therapy [1]. One aHUS patient aged 
30 months was reported as developing HAHAs; this patient 
had inadequate Ctrough (17.1 µg/ml), ongoing hemolytic 
activity, and non-responsive TMA after the start of treat-
ment [60].
3.3.6  Plasma Infusion and Exchange
As expected, plasma exchange and plasma infusion have a 
clear influence on the CL of eculizumab, and subsequently 
led to a marked reduction in half-life (see Table 3). CL 
was measured in aHUS patients with plasma exchange and 
increased from 14.6 to 3660 ml/h, with an estimated half-life 
of 1.26 h. Therefore, it is recommended to supplement an 
extra dose of eculizumab (600 mg, unless the patient only 
received 300 mg in the maintenance phase, and then only 
300 mg of supplementation) within 60 min after plasma 
exchange. In case of infusion of fresh frozen plasma, it is 
recommended to administer 300 mg, in addition to the nor-
mal dose, 60 min prior to infusion [41, 58].
3.3.7  Effect of Pregnancy
No formal PK studies have been performed for pregnant 
women receiving eculizumab. Different articles and case 
reports describe the use of eculizumab in pregnant women 
with either PNH or aHUS [64–70]. Kelly et al. reported 
therapeutic concentrations of eculizumab measured in two 
of three PNH patients, without detectable eculizumab in 
cord blood and breast milk [68]. Furthermore, Servais et al. 
described five pregnancies in three aHUS patients receiv-
ing eculizumab, and, as similarly reported by Kelly et al., 
no eculizumab was detected in cord and neonatal blood; 
however, the eculizumab dose had to be increased in two 
patients, as high as 1800 mg every 2 weeks, to maintain 
complement blockage. Both patients showed signs of partial 
blockage in the first trimester [69]. In contrast to the pre-
viously discussed studies in a cohort of 61 pregnant PNH 
patients, in 35% of the cord blood samples eculizumab con-
centrations were detectable, ranging from 11.8 to 21.2 µg/
mL, which is in contrast to the breast milk samples where 
eculizumab was not detectable [70]. Moreover, pregnancy 
was associated with lower, and even inadequate, Ctrough lev-
els of eculizumab. Of the 61 patients evaluated, half needed 
an increased dose of eculizumab [70].
4  Pharmacodynamic (PD) Properties 
of Eculizumab
Formal dose and concentration response studies were not 
performed in any of the patient groups reported below. Data 
from various clinical trials were used to assess the efficacy 
and exposure–response of eculizumab; however, only 
the data published regarding PD in relation to PK will be 
described in this review.
4.1  Monitoring of Eculizumab Therapy
In all trials conducted by the pharmaceutical company, 
hemolytic activity was used to determine the PD properties 
of eculizumab [6, 60]. Hemolytic activity reflects total com-
plement activity (reported as CH50) by testing the capacity 
of patient serum to lyse sheep or chicken erythrocytes coated 
with antibodies. In case of a functional complement system, 
the CP will be activated, subsequently leading to C5b-C9 
deposition on the erythrocytes and thus causing hemolysis. 
CH50 levels correlated with eculizumab serum trough lev-
els, and a completely blocked complement (no hemolytic 
activity measured) was the aim of treatment.
It is important to realize that besides the classical hemo-
lytic assay based on lysis of erythrocytes, various other 
assays have been introduced to measure CH50. Further-
more, C5 function and AP activity (AP50) are also reported 
as a marker of eculizumab effectiveness [71]. In case of 
eculizumab levels > 100 µg/ml, undetectable CH50, AP50, 
and normal C5 levels with inhibited C5 function have been 
reported [71]. There are different (commercial) assays 
available to measure these markers, of which the so called 
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‘Wieslab’ ELISA is quite commonly used. However, more 
studies are needed to explore the relation between AP50 and 
eculizumab trough levels since AP50 levels are not totally 
suppressed despite high eculizumab levels [71, 72].
4.2  Exposure–Effect Relationship of Eculizumab
The exposure–effect relationship in the phase I and II trials 
in RA, SLE, and IMG patients was mainly evaluated using 
the serum hemolytic activity to assess complement inhibi-
tion [3]. The results of the single-dose studies in RA (C97-
001) and SLE (C97-002) showed a concentration-dependent 
inhibition of hemolytic activity, with an inverse relation-
ship between eculizumab concentration and C5 comple-
ment blockade. Hemolytic activity was completely blocked 
within 15 min in almost all patients who received a 2.0 mg/
kg dose, but hemolytic activity reappeared within 2 days. 
By increasing the dose to 4 or 8 mg/kg, complement activ-
ity was completely suppressed for 7–14 and 11–21 days, 
respectively. Complete blockade of complement hemolytic 
activity was measured at eculizumab concentrations as low 
as 29–55 µg/ml and 11–35 µg/ml in RA and SLE patients, 
respectively [3].
The maximum PD effect was modeled using a maximum 
effect  (Emax) model using the above-described data from RA 
patients pooled with data of IMG and PNH patients, with 
a half maximal effective concentration (EC50) of 43 µg/ml 
(95% CI 39.04–47.78) [3]. Since eculizumab concentrations 
are reported in both the bound to C5 and unbound propor-
tion of eculizumab, this could indicate an overestimation 
of the required eculizumab concentration for complement 
blockade [73]. The EMA scientific report using pooled data 
from all single- and multiple-dose studies (performed in 
various patient populations) suggested that an eculizumab 
serum concentration of 35 µg/ml is sufficient to completely 
block complement activation. Hence, the dosing schedule 
of 600 mg in the initiation phase, followed by 900 mg every 
2 weeks, was selected as the most optimal dosing regimen to 
suppress complement inhibition in almost all PNH patients 
(Table 2) [3, 42].
Nonetheless, based on a meta-analysis of data from 177 
PNH patients, a higher target exposure was recommended 
for patients with aHUS. In this cohort of PNH patients, some 
patients (up to 10%) had remaining complement activity [16, 
57]. It was expected that this residual activity could result in 
clinical manifestations in the aHUS patient group. The main 
expected clinical manifestations reported were the potential 
rapid loss of kidney function in case of insufficient block-
age, with ongoing active TMA [61]. In the FDA approval 
package, an analysis is shown that describes the necessity of 
a minimal eculizumab concentration of 50 µg/ml to achieve 
a > 90% decrease in free C5 [56]. Hence, in aHUS patients, 
higher eculizumab concentrations of 50–100 µg/ml for com-
plete complement blockade are recommended (Table 2).
4.2.1  Paroxysmal Nocturnal Hemoglobinuria
Different trials, i.e. C02-001 (n = 11), TRIUMPH (n = 43) 
and SHEPHERD (n = 97), as well as the extension trial 
comprising all previously reported patients (E05-001), 
reported efficacy of eculizumab in PNH [1, 2, 74]. To assess 
PD properties, serum hemolytic activity was evaluated. 
Unfortunately, both the TRIUMPH and SHEPHERD trials 
mentioned the use of the serum hemolytic assay, however 
no values were reported [1, 16]. Eculizumab concentra-
tions in relation to hemolytic activity were only described 
in the extension trial. In total, 43 patients from the TRI-
UMPH trial and 97 patients from the SHEPHERD trial 
were included. Overall, 36% of patients had eculizumab 
concentrations < 35 µg/ml after the first infusion of eculi-
zumab [57], of whom 36% and 74% exhibited hemolytic 
activity (> 20%). During the follow-up period, Ctrough con-
centrations < 35 µg/ml were repeatedly observed in 14 (10%) 
patients. In half of these patients, complement activity was 
blocked by decreasing the interval between administrations. 
In total, 21 patients from the entire population experienced 
a median of 22 decreases in dosing interval [57].
Reiss et al. described the results of a phase I/II study in 
seven pediatric PNH patients, all > 11 years of age. Eculi-
zumab concentrations > 124 µg/ml correlated with complete 
complement blockade. The Cmax and Ctrough concentration, 
together with the AUC of eculizumab, were associated with 
a change in lactate dehydrogenase (LDH) [59].
de Latour et al. assessed the efficacy of eculizumab in 22 
PNH patients [55]. The association between CH50 and LDH 
was assessed using a linear mixed model with intercept and 
slope for therapy duration. The association between CH50 
and eculizumab was analyzed using generalized linear models 
with logistic link function. Suboptimal eculizumab concentra-
tions (< 35 µg/ml) were reported in 5% of the samples. Fur-
thermore, CH50 measured in these patients (median follow-up 
of 13 months, with a minimum of 6 months of treatment) 
showed a CH50 > 10% in 49% of patients prior to the next 
eculizumab administration. Complete blockade of comple-
ment (CH50 < 10%) was associated with lower LDH levels 
(longitudinal Tobit regression model). An increase in CH50 
by 1.4% per 100 U/L (95% CI 0.03–2.7) increase of LDH was 
observed. All patients with eculizumab serum levels > 150 µg/
ml did not experience breakthrough hemolysis [55].
4.2.2  Atypical Hemolytic Uremic Syndrome
To analyze the efficacy of eculizumab in aHUS, free C5 is 
used as a read-out. In both prospective studies (C08-002 and 
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C08-003), a median reduction of 50 and 62%, respectively, 
was observed in C5 activity, and eculizumab Ctrough levels 
> 50 µg/ml correlated with a decrease in free C5 by > 90% 
[56]. CH50 levels were either reduced or were undetect-
able after 7 days of therapy [56]. After 24 weeks, complete 
inhibition of complement activity was reported in all partici-
pants; however, no specific values were reported regarding 
complement activation and eculizumab concentrations [6, 
75]. A prospective study in pediatric aHUS patients (C10-
003) did not report complement inhibition data, only that all 
patients showed signs indicative of complement inhibition 
after 24 h [60].
Gatault et al. described a concentration–effect relationship 
in seven aHUS patients and two PNH patients treated with 
eculizumab. With the regression technique (A = 20.6 × exp 
(−0.083 × C), the relation between hemolytic activity and 
PK was described. No lysis was detected when Ctrough levels 
were > 20 µg/ml, using a CH50 SPAPLUS kit that measures 
liposome lysis. However, Gatault et al. state that this assay 
is less sensitive and is hence not recommended. They also 
used an ELISA kit to measure C9, to detect low to moderate 
depression of complement activity that corresponds with 
CH50. Complement activity was detected with this assay 
when Ctrough levels were < 59 µg/ml [9].
4.2.3  Other Populations
Jodele et al. described the correlation–effect relationship 
between eculizumab concentrations and CH50 levels in 
365 paired samples of 18 patients with HSCT-TMA [18]. 
The eculizumab concentration necessary to fully block 
complement activation (CH50 < 10%) was determined with 
a receiver operating characteristic (ROC) curve to maximize 
the Youden’s Index (specificity + sensitivity − 1). Eculi-
zumab levels > 99 µg/ml were associated with a suppressed 
CH50 [18]. PD data are sporadically reported for gMG. An 
EMA assessment report describes the population PK/PD 
analysis, with free C5 as the target engagement and hemo-
lytic activity for proof of pharmacology [5].
5  Covariates for Eculizumab PD
In some patients with PNH or aHUS, a suboptimal (defined as 
persistent disease activity) response to eculizumab is described 
despite adequate eculizumab concentrations and suppression 
of CH50. Various potential mechanisms have been proposed 
to explain this phenomenon. Although CH50 is suppressed, 
sC5b-C9 levels can remain elevated, indicating ongoing com-
plement activation. Another possibility could be the decreased 
CL of sC5b-C9 complexes due to the binding of eculizumab 
to C5b [71].
In patients with PNH, long-term studies revealed break-
through hemolysis during maintenance therapy, and half of 
all patients had insufficient blockage of complement prior to 
the next infusion [55]. Different etiologies could be the cause 
of this ongoing hemolysis. The most prominent etiologies are 
considered to be C3 opsonization of erythrocytes, making 
them more vulnerable to hemolysis, and insufficient C5 block-
age by either inadequate Ctrough levels or in case of strong com-
plement activation [76, 77]. Multiple studies have described 
ex vivo detection of hemolytic activity, indicating ongoing 
complement activation, despite eculizumab treatment with 
adequate Ctrough levels. Besides discordant results between dif-
ferent assays used in the clinics, remaining hemolytic activity 
could persist in light of strong complement activation [76]. 
Careful characterization and monitoring of these patients is 
necessary to understand this mechanism [76].
Nishimura et al. described 11 PNH patients (3.2% of the 
PNH population receiving eculizumab) with a poor response 
to eculizumab [78]. Despite adequate Cmax and Ctrough concen-
trations, patients had ongoing hemolysis, and all had a single 
missense C5 heterozygous sequence variant c.2654G → A, 
which corresponds to the polymorphism p.Arg885His. This 
genetic variant prohibits the binding of eculizumab to C5, and 
subsequently C5 capacity to form the lytic C5b-C9 remains 
present. Further screening revealed the same prevalence of 
this variant among healthy controls in Japan [78]. Separately, 
an Asian PNH patient with poor response to eculizumab had 
a c.2653C → T mutation in C5, which predicts p.Arg885Cys. 
Both mutations were not found in a cohort of 220 Chinese 
PNH patients and 259 healthy controls [79]. Schatz-Jakobsen 
et al. investigated the structural changes in C5 as a conse-
quence of these mutations. Due to the replacement of argi-
nine by histidine or cysteine, the arginine-binding pocket is too 
small and hence eculizumab cannot bind to C5 [80].
5.1  Incremental Value of Therapeutic Drug 
Monitoring of Eculizumab Therapy
We have reviewed the basic pharmacology of eculizumab in 
all diseases for which this drug is currently licensed. Next, 
we described the PK and PK–PD relations, as well as covari-
ates that impact both the PK and PD. Striking is the high 
interindividual variation. We advocate for an individualized 
approach to provide the best tailored care.
We hypothesize that by performing therapeutic drug 
monitoring (TDM), one could adjust the dose and/or dos-
ing intervals and thereby maximize treatment response and 
reduce treatment costs. As an illustration, we performed 
a simulation study of the effect of TDM of eculizumab 
in PNH patients. We simulated a population of 1000 vir-
tual adult patients based on the population PK and PD of 
eculizumab in PNH patients as described by the pharma-
ceutical company, with an average body weight of 70 kg 
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(20% variation) [73]. After simulation of the virtual indi-
viduals, the individual PK parameters for each individual 
were used to predict the steady-state exposure after dose 
adaptation. We simulated the PK of eculizumab at steady 
state (after 8 weeks of standard treatment, including the 
induction phase) and applied a protocol for TDM based on 
the measurement of the steady state Ctrough, using the fol-
lowing algorithm: the absolute dose at each administration 
(900 mg) remained the same, but the dosing interval was 
adjusted, based on the measured Ctrough levels. When Ctrough 
levels were below the target of 30 µg/ml, we decreased 
the dosing interval from 2 weeks to 1 week. When the 
Ctrough was between 30 and 90 µg/ml, the usual 2-week 
interval was maintained. At higher exposure, the dosing 
intervals were extended: a Ctrough of 90–120 resulted in a 
3-week dosing interval, a Ctrough between 120 and 210 µg/
ml resulted in a 4-week interval, and a Ctrough > 210 µg/ml 
resulted in an interval of 5 weeks. The results of the simu-
lation are presented in Fig. 2, where the predicted Ctrough 
and associated inhibition of C5 activity are shown before 
and after the TDM intervention. Without TDM, large inter-
individual variation in predicted exposure can be observed, 
with a median Ctrough level of 76 µg/ml (range 4–362) when 
using the standard dose regimen. By using TDM, median 
Ctrough levels decrease to 58 µg/ml (range 30–131) [Fig. 2a]. 
Furthermore, simultaneously with decreasing the range 
of Ctrough levels, a decrease in the variation of C5 inhibi-
tion could be observed, with more patients reaching target 
attainment (Fig. 2b). Moreover, with our TDM regimen, an 
overall cost reduction of 11% in 1000 simulated patients 
was achieved by diminishing eculizumab administrations. 
We calculated the costs of eculizumab administrations 
alone per patient for 1 year of treatment and compared this 
with standard treatment (patients who are treated for 1 year 
according to the treatment scheme described in Table 2). 
Every patient received 8 weeks of standard therapy, after 
which TDM was applied with adjustment of the interval 
between eculizumab administrations. Costs largely depend 
on the cumulative dose per patient, ranging from €211,618 
per patient per year with a 5-weekly interval, to €726,524 
per patient per year with a 1-weekly interval.
Of note, studies reporting TDM in patients with aHUS 
and HSCT-TMA have increased substantially [9, 10, 18, 
52]. However, remarkable is the lack of studies regarding 
TDM in patients with PNH. Future studies should give more 
insight into the possibility and potential risks of TDM in 
patients with PNH.
In conclusion, we would like to stress the potential of 
TDM for the use of eculizumab in various diseases. To fully 
determine the efficacy of therapy, we advise monitoring 
both eculizumab serum levels and complement blockade by 
CH50. One could argue that eculizumab levels alone would 
be sufficient since there seems to be a clear correlation 
between Ctrough and complement blockade. In our opinion, 
CH50 is especially important in the case of clinical deterio-
ration despite adequate exposure.
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Fig. 2  Effect of TDM in PNH. TDM can guide therapy adjustments. 
We simulated 1000 PNH patients and assessed the pharmacokinet-
ics of eculizumab at steady state (after 8  weeks of standard treat-
ment, including the induction phase) and applied a protocol for TDM 
based on the measurement of the steady-state Ctrough, using the fol-
lowing algorithm: the absolute dose at each administration (900 mg) 
remained the same, but the dosing interval was adjusted, based on the 
measured Ctrough levels. When Ctrough levels were below the target of 
30 µg/ml, we decreased the dosing interval from 2 weeks to 1 week. 
When the Ctrough was between 30 and 90  µg/ml, the usual 2-week 
interval was maintained. At higher exposure, the dosing intervals 
were extended: a Ctrough of 90–120 resulted in a 3-week dosing inter-
val, a Ctrough between 120 and 210 µg/ml resulted in a 4-week inter-
val, and a Ctrough > 210 µg/ml resulted in an interval of 5 weeks. Large 
variations are observed in Ctrough levels when simulated in 1000 PNH 
patients according to the compartment model, as described by the 
pharmaceutical company. (a) A substantial number of patients do not 
reach the target of 35 µg/ml (red dotted line), and, in contrast, some 
patients reach Ctrough levels up to 362 µg/ml. (b) By applying TDM, 
the distribution can be largely diminished, with almost all patients 
reaching target attainment and adequate inhibition of C5 activity, as 
measured by serum complement hemolytic activity. TDM therapeutic 
drug monitoring, PNH paroxysmal nocturnal hemoglobinuria, Ctrough 
trough concentration
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6  Discussion
Eculizumab is known to be one of the most expensive 
orphan drugs worldwide. Despite multiple studies in various 
patient populations, little is known regarding the potential 
for TDM in patients receiving eculizumab. In this review, we 
extensively discussed the PK and PD parameters in various 
patient populations treated with eculizumab (PNH, aHUS, 
gMG, and HSCT-TMA). Furthermore, strategies to target 
optimal Ctrough levels via TDM by preserving adequate com-
plement blockade are discussed.
Although CH50 is used as a PD outcome in most of the 
articles, one should realize the high diversity in the assays 
used. Taken together with the uncertain concentration of 
both the bound and unbound proportion of eculizumab 
measured in the assay, we would advocate setting up a close 
collaboration with a national reference laboratory in each 
country. Furthermore, the potential influence of high solu-
ble C5b-C9 levels on eculizumab levels should be further 
evaluated.
Eculizumab was first approved for PNH patients, with a 
set Ctrough target level of 35 µg/ml based on multiple-dose 
studies performed in PNH patients. On the other hand, the 
determined Ctrough target level of 50–100 µg/ml in aHUS 
patients is based on assumptions rather than on PK mod-
eling. Taking into account the breakthrough hemolysis in 
PNH patients with a Ctrough of 35 µg/ml, and the risks of 
ongoing TMA in aHUS patients, the Ctrough target was set 
at 50–100 µg/ml. Especially in patients with aHUS, the 
duration of eculizumab treatment is a highly debated topic. 
Important to note is the trend towards the withdrawal of 
eculizumab in patients with aHUS and to only reinitiate 
treatment at the recurrence of disease [34, 81, 82]. Of note, 
most studies focused on complete complement blockade to 
prevent ongoing disease activity; however, it is unknown if 
complete blockage is necessary to prevent disease progres-
sion in the acute and/or remission phase. Ardissino et al. 
recently described eculizumab treatment in aHUS patients 
with impaired instead of fully blocked complement activity 
[83]. With CH50 < 30% instead of completely suppressed, 
no recurrences were observed.
Eculizumab has only recently been approved for the 
treatment of gMG. Striking is the lack of data correlating 
complement inhibition to clinical deterioration in patients 
with gMG. Furthermore, no relation between eculizumab 
concentration and the primary efficacy endpoint was seen; 
hence, monitoring complement inhibition while receiving 
eculizumab therapy needs to be evaluated. Future (exten-
sion) studies should provide more data regarding eculi-
zumab treatment in gMG. Since IVIgs are used as therapy 
in gMG, one should realize that eculizumab Ctrough levels 
could therefore be influenced. During trials, patients had a 
washout period before receiving eculizumab.
Since the introduction of eculizumab as a first comple-
ment inhibitor, many trials have been conducted to study 
the effect of improved and alternative complement inhibi-
tors. Phase III trials are currently being conducted to study 
the long-acting variant of eculizumab—ravulizumab—in 
patients with PNH and aHUS [84, 85]. In addition to drugs 
targeting C5, many other components of the complement 
system have been proposed as a target to halter complement 
activation. Various complement-targeted drugs have reached 
late-stage clinical trial development [4], however until now, 
eculizumab remains the gold-standard treatment for patients 
with PNH and aHUS.
7  Conclusions
To minimize unnecessary use of the highly expensive 
orphan drug eculizumab, and to assess the optimal treat-
ment scheme, TDM may be performed using eculizumab 
Ctrough levels. Furthermore, disease activity should be moni-
tored to look for possibilities to taper treatment. Treatment 
algorithms should be developed to explore the possibility 
of individual dosing regimens based on set Ctrough levels, 
together with CH50.
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